{
  "first_published_at": "2012-01-12", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON140667", 
  "title": "Statins: risk of hyperglycaemia and diabetes", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 125, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Statins: risk of hyperglycaemia and diabetes</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Statin use may be associated with a level of hyperglycaemia in some patients where formal diabetes care is appropriate. The risk appears to be mainly in patients already at increased risk of developing diabetes. However, the overall benefits of statins strongly outweigh any risks, including in those at risk of developing diabetes or those with pre-existing diabetes.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Statin use may be associated with a level of hyperglycaemia in some patients where formal diabetes care is appropriate. The risk appears to be mainly in patients already at increased risk of developing diabetes. However, the overall benefits of statins strongly outweigh any risks, including in those at risk of developing diabetes or those with pre-existing diabetes<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Statins are one of the most widely prescribed drug classes in Europe for lipid control and cardiovascular prophylaxis, and prescribing is continuing to grow. Between 2002 and 2008 in the UK, statin prevalence has doubled for those older than 40 year and quadrupled for those older than 80 years. &#160;</p>\n\n<p>In 2010, a clinical trial meta-analysis reported that statin therapy overall was associated with a slightly increased risk of new onset diabetes (NOD).<cite>Sattar N, et al. Lancet 2010; 375: 735&#8211;42.</cite> Although a small risk (odds ratio 1.09 [95% CI 1.02&#8211;1.17]), given the extent of prescribing even a relatively small increase in the risk of NOD could potentially result in a significant number of additional cases of diabetes per year. Treatment of 255 (95% CI 150&#8211;852) patients with statins for 4 years resulted in one extra case of diabetes.<span class=\"super\">1</span> However, the evidence suggests that risk depends markedly on individual risk factors. &#160;</p>\n\n<p>Comparison of studies across the statin class is limited by numerous factors including differences in patient populations, duration of study, and dose of statin used. Furthermore, the endpoint used to diagnose diabetes varied in terms of frequency and time of analysis, and whether fasting blood glucose or, more rarely, HbA1c levels were measured. Importantly, a recent study<cite>Waters DD, et al. J Am Coll Cardiol 2011; 57: 1535&#8211;45</cite> of the association between atorvastatin and NOD suggests that stratification of patients by risk factors may yield different conclusions to those drawn when considering the patient population as a whole. &#160;</p>\n\n<p>There is sufficient evidence to support an association between statin use and NOD. However, the risk appears to be mainly in patients already at increased risk of developing diabetes. Raised fasting blood glucose at baseline is a key factor in determining this increased risk and may be sufficient to identify those at risk. Other risk factors include: &#160;</p>\n\n<ul>\n<li>history of hypertension</li>\n\n<li>raised triglycerides</li>\n\n<li>raised body mass index at baseline</li>\n</ul>\n\n<p>There are limited data to support a further increased risk of diabetes with intensive high-dose atorvastatin or simvastatin therapy.<cite>Preiss D, et al. JAMA 2011; 305: 2556&#8211;64.</cite> Given the important effect of patient characteristics on the risk of diabetes and the variability of the available studies, there are currently insufficient data to exclude any statin from the possibility of exacerbating the risk of NOD in a susceptible individual. &#160;</p>\n\n<p>Despite the increased risk of NOD in susceptible individuals, studies clearly show a benefit of statins in reducing major cardiovascular events.<span class=\"super\">3&#160;</span><cite>The Cholesterol Treatment Trialists&#8217; Collaborators. Lancet 2005; 366: 1267&#8211;78.</cite><span class=\"super\">&#160;</span><cite>The Cholesterol Treatment Trialists&#8217; Collaborators. Lancet 2008; 371: 117&#8211;25.</cite> The overall benefits of statins strongly outweigh any risks, including in those at risk of diabetes and those with diabetes at baseline. However, steps should be taken to ascertain patients who are at risk, to identify the onset of NOD, and to manage the condition appropriately. Patients at risk should be monitored both clinically and biochemically according to national guidelines. &#160;</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong> &#160;</p>\n\n<ul>\n<li>There is sufficient evidence to support an association between statin use and NOD</li>\n\n<li>The risk appears to be mainly in patients already at increased risk of developing diabetes</li>\n\n<li>Raised fasting blood glucose at baseline is a key risk factor. Other risk factors include: a history of hypertension; raised triglycerides; and raised body mass index at baseline</li>\n\n<li>Patients at risk should be monitored both clinically and biochemically according to national guidelines</li>\n\n<li>The level of risk of NOD may vary between statins. However, there is insufficient evidence to confirm or exclude an increased risk for any member of the statin class</li>\n\n<li>The reduced vascular risk from statin therapy outweighs the risk of diabetes, which is therefore not a reason for stopping statin treatment</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>BNF section 2.12 <a target=\"_blank\" href=\"http://bnf.org/bnf/bnf/current/33422.htm?q=statins&#38;t=search&#38;ss=text&#38;p=2#_hit\">Lipid-regulating drugs</a></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Statins are one of the most widely prescribed drug classes in Europe for lipid control and cardiovascular prophylaxis, and prescribing is continuing to grow. Between 2002 and 2008 in the UK, statin prevalence has doubled for those older than 40 year and quadrupled for those older than 80 years. &#160;</p>\n\n<p>In 2010, a clinical trial meta-analysis reported that statin therapy overall was associated with a slightly increased risk of new onset diabetes (NOD).<cite>Sattar N, et al. Lancet 2010; 375: 735&#8211;42.</cite> Although a small risk (odds ratio 1.09 [95% CI 1.02&#8211;1.17]), given the extent of prescribing even a relatively small increase in the risk of NOD could potentially result in a significant number of additional cases of diabetes per year. Treatment of 255 (95% CI 150&#8211;852) patients with statins for 4 years resulted in one extra case of diabetes.<span class=\"super\">1</span> However, the evidence suggests that risk depends markedly on individual risk factors. &#160;</p>\n\n<p>Comparison of studies across the statin class is limited by numerous factors including differences in patient populations, duration of study, and dose of statin used. Furthermore, the endpoint used to diagnose diabetes varied in terms of frequency and time of analysis, and whether fasting blood glucose or, more rarely, HbA1c levels were measured. Importantly, a recent study<cite>Waters DD, et al. J Am Coll Cardiol 2011; 57: 1535&#8211;45</cite> of the association between atorvastatin and NOD suggests that stratification of patients by risk factors may yield different conclusions to those drawn when considering the patient population as a whole. &#160;</p>\n\n<p>There is sufficient evidence to support an association between statin use and NOD. However, the risk appears to be mainly in patients already at increased risk of developing diabetes. Raised fasting blood glucose at baseline is a key factor in determining this increased risk and may be sufficient to identify those at risk. Other risk factors include: &#160;</p>\n\n<ul>\n<li>history of hypertension</li>\n\n<li>raised triglycerides</li>\n\n<li>raised body mass index at baseline</li>\n</ul>\n\n<p>There are limited data to support a further increased risk of diabetes with intensive high-dose atorvastatin or simvastatin therapy.<cite>Preiss D, et al. JAMA 2011; 305: 2556&#8211;64.</cite> Given the important effect of patient characteristics on the risk of diabetes and the variability of the available studies, there are currently insufficient data to exclude any statin from the possibility of exacerbating the risk of NOD in a susceptible individual. &#160;</p>\n\n<p>Despite the increased risk of NOD in susceptible individuals, studies clearly show a benefit of statins in reducing major cardiovascular events.<span class=\"super\">3&#160;</span><cite>The Cholesterol Treatment Trialists&#8217; Collaborators. Lancet 2005; 366: 1267&#8211;78.</cite><span class=\"super\">&#160;</span><cite>The Cholesterol Treatment Trialists&#8217; Collaborators. Lancet 2008; 371: 117&#8211;25.</cite> The overall benefits of statins strongly outweigh any risks, including in those at risk of diabetes and those with diabetes at baseline. However, steps should be taken to ascertain patients who are at risk, to identify the onset of NOD, and to manage the condition appropriately. Patients at risk should be monitored both clinically and biochemically according to national guidelines. &#160;</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong> &#160;</p>\n\n<ul>\n<li>There is sufficient evidence to support an association between statin use and NOD</li>\n\n<li>The risk appears to be mainly in patients already at increased risk of developing diabetes</li>\n\n<li>Raised fasting blood glucose at baseline is a key risk factor. Other risk factors include: a history of hypertension; raised triglycerides; and raised body mass index at baseline</li>\n\n<li>Patients at risk should be monitored both clinically and biochemically according to national guidelines</li>\n\n<li>The level of risk of NOD may vary between statins. However, there is insufficient evidence to confirm or exclude an increased risk for any member of the statin class</li>\n\n<li>The reduced vascular risk from statin therapy outweighs the risk of diabetes, which is therefore not a reason for stopping statin treatment</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>BNF section 2.12 <a target=\"_blank\" href=\"http://bnf.org/bnf/bnf/current/33422.htm?q=statins&amp;t=search&amp;ss=text&amp;p=2#_hit\">Lipid-regulating drugs</a></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-01-01", 
  "date_last_modified": "2012-02-14", 
  "_assets": [], 
  "_item_id": 125, 
  "summary": "Statin use may be associated with a level of hyperglycaemia in some patients where formal diabetes care is appropriate. The risk appears to be mainly in patients already at increased risk of developing diabetes. However, the overall benefits of statins strongly outweigh any risks, including in those at risk of developing diabetes or those with pre-existing diabetes", 
  "body": "Article date: January 2012\n\nStatins are one of the most widely prescribed drug classes in Europe for lipid control and cardiovascular prophylaxis, and prescribing is continuing to grow. Between 2002 and 2008 in the UK, statin prevalence has doubled for those older than 40 year and quadrupled for those older than 80 years.  \n\nIn 2010, a clinical trial meta-analysis reported that statin therapy overall was associated with a slightly increased risk of new onset diabetes (NOD).[^1] Although a small risk (odds ratio 1.09 [95% CI 1.02–1.17]), given the extent of prescribing even a relatively small increase in the risk of NOD could potentially result in a significant number of additional cases of diabetes per year. Treatment of 255 (95% CI 150–852) patients with statins for 4 years resulted in one extra case of diabetes. 1 However, the evidence suggests that risk depends markedly on individual risk factors.  \n\nComparison of studies across the statin class is limited by numerous factors including differences in patient populations, duration of study, and dose of statin used. Furthermore, the endpoint used to diagnose diabetes varied in terms of frequency and time of analysis, and whether fasting blood glucose or, more rarely, HbA1c levels were measured. Importantly, a recent study[^2] of the association between atorvastatin and NOD suggests that stratification of patients by risk factors may yield different conclusions to those drawn when considering the patient population as a whole.  \n\nThere is sufficient evidence to support an association between statin use and NOD. However, the risk appears to be mainly in patients already at increased risk of developing diabetes. Raised fasting blood glucose at baseline is a key factor in determining this increased risk and may be sufficient to identify those at risk. Other risk factors include:    \n  \n  * history of hypertension  \n  * raised triglycerides  \n  * raised body mass index at baseline  \n  \nThere are limited data to support a further increased risk of diabetes with intensive high-dose atorvastatin or simvastatin therapy.[^3] Given the important effect of patient characteristics on the risk of diabetes and the variability of the available studies, there are currently insufficient data to exclude any statin from the possibility of exacerbating the risk of NOD in a susceptible individual.  \n\nDespite the increased risk of NOD in susceptible individuals, studies clearly show a benefit of statins in reducing major cardiovascular events.3 [^4]  [^5] The overall benefits of statins strongly outweigh any risks, including in those at risk of diabetes and those with diabetes at baseline. However, steps should be taken to ascertain patients who are at risk, to identify the onset of NOD, and to manage the condition appropriately. Patients at risk should be monitored both clinically and biochemically according to national guidelines.  \n\nAdvice for healthcare professionals:    \n  \n  * There is sufficient evidence to support an association between statin use and NOD  \n  * The risk appears to be mainly in patients already at increased risk of developing diabetes  \n  * Raised fasting blood glucose at baseline is a key risk factor. Other risk factors include: a history of hypertension; raised triglycerides; and raised body mass index at baseline  \n  * Patients at risk should be monitored both clinically and biochemically according to national guidelines  \n  * The level of risk of NOD may vary between statins. However, there is insufficient evidence to confirm or exclude an increased risk for any member of the statin class  \n  * The reduced vascular risk from statin therapy outweighs the risk of diabetes, which is therefore not a reason for stopping statin treatment  \n  \nFurther information:\n\nBNF section 2.12 [Lipid-regulating drugs](http://bnf.org/bnf/bnf/current/33422.htm?q=statins&t=search&ss=text&p=2#_hit)\n\n[^1]: Sattar N, et al. Lancet 2010; 375: 735–42.\n\n[^2]: Waters DD, et al. J Am Coll Cardiol 2011; 57: 1535–45\n\n[^3]: Preiss D, et al. JAMA 2011; 305: 2556–64.\n\n[^4]: The Cholesterol Treatment Trialists’ Collaborators. Lancet 2005; 366: 1267–78.\n\n[^5]: The Cholesterol Treatment Trialists’ Collaborators. Lancet 2008; 371: 117–25.\n"
}